Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. Glioblastoma (GBM) is the most aggressive and frequent subtype of all malignant gliomas. At the time of recurrence, therapeutic options are lacking. Ortataxel, a second-generation taxane was reported to be effective in pre-clinical and phase I clinical studies. The aim of this study was to evaluate a potential therapeutic activity of ortataxel in patients with GBM recurring after surgery and first line treatment. In this phase II study, according to a two stage design, adult patients with histologically confirmed GBM in recurrence after surgery or biopsy, standard radiotherapy and chemotherapy with temozolomide were considered eligible. Patients included were treated with ortataxel 75 mg/m i.v. every
Lung Cancer Drug: ortataxel Phase 2 Detailed Description: OBJECTIVES: * Determine the overall response rate, including partial and complete response, in patients with taxane-resistant non-small cell lung cancer treated with BAY 59-8862. * Determine the overall survival of patients treated with this drug. * Determine duration of response and time to progression in patients
cancer.Condition or disease Intervention/treatment Phase Kidney Cancer Drug: ortataxel Phase 2 Detailed Description: OBJECTIVES: * Determine the overall tumor response rate, including complete response (CR) and partial response (PR) rate, in patients with advanced renal cell cancer treated with BAY 59-8862. * Determine the overall survival in patients treated with this drug
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma An Efficacy Study Of Ortataxel In Recurrent Glioblastoma - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms studies before adding more. An Efficacy Study Of Ortataxel In Recurrent Glioblastoma (Ortataxel) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT01989884